Open-label, Single Center, Single-arm, Phase 2 Study of Neoadjuvant Pembrolizumab in Combination With Carboplatin and Paclitaxel in Patients With Stage 1 cT1b-T1cN0M0 Triple Negative Breast Cancer

NCT06318897 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

28

Enrollment

OTHER

Sponsor class

Conditions

Stage 1 cT1b-T1cN0M0
Triple Negative Breast Cancer

Interventions

DRUG: Carboplatin
DRUG: Paclitaxel
DRUG: Pembrolizumab
DRUG: Doxorubicin
DRUG: Cyclophosphamide

Sponsor

M.D. Anderson Cancer Center